MC
VRTX icon

Moors & Cabot’s Vertex Pharmaceuticals VRTX Stock Holding History

Moors & Cabot’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-100
Closed -$5K – 923
2022
Q1 		$5K Buy
100
+98
+4,900% +$23.3K ﹤0.01% 866
2021
Q4 		$2K Buy
+2
New +$389 ﹤0.01% 898

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Moors & Cabot's VRTX Position: Q2 2026 in Review

Moors & Cabot reduced its Vertex Pharmaceuticals (VRTX) stake by 4.7% in Q2 2026, selling an estimated $73.6K and leaving 3,390 shares worth $1.68M. The position accounts for 0.07% of the portfolio, ranked #267.

Moors & Cabot first reported a position in VRTX in Q4 2019 and has held it in 24 quarters since. The position peaked at $2.67M in Q1 2025. 1,761 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • Moors & Cabot held 3,390 shares of Vertex Pharmaceuticals worth $1.68M as of Q2 2026.
  • Moors & Cabot sold 166 Vertex Pharmaceuticals shares in Q2 2026, an estimated $73.6K.
  • Vertex Pharmaceuticals made up 0.07% of Moors & Cabot's portfolio in Q2 2026, its #267 holding.
  • Moors & Cabot first reported a position in Vertex Pharmaceuticals in Q4 2019 and has held it in 24 quarters since.
  • Moors & Cabot's Vertex Pharmaceuticals position peaked at $2.67M in Q1 2025.
  • 1,761 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Moors & Cabot's 13F filing for Q2 2026, filed 10 Aug 2026.